- Home
- AVBP
as 05-20-2024 1:34pm EST
ArriVent BioPharma Inc is a clinical stage biopharmaceutical company dedicated to the identification, development and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize team's deep drug development experience to maximize the potential of lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.
| Founded: | 2021 | Country: | United States |
| Employees: | N/A | City: | NEWTOWN SQUARE |
| Market Cap: | 577.8M | IPO Year: | 2024 |
| Target Price: | $29.25 | AVG Volume (30 days): | 172.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.23 | EPS Growth: | N/A |
| 52 Week Low/High: | $14.35 - $25.95 | Next Earning Date: | 05-08-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 83.33% |
Share on Social Networks:
Stock Insider Trading Activity of ARRIVENT BIOPHARMA INC (AVBP)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| GORDON CARL L | AVBP | Director10% Owner | Jan 30 '24 | Buy | $18.00 | 222,222 | $3,999,996.00 | 1,513,664 | SEC Form 4 |
| GORDON CARL L | AVBP | Director10% Owner | Jan 30 '24 | Buy | $18.00 | 222,222 | $3,999,996.00 | 1,513,664 | SEC Form 4 |
| ORBIMED ADVISORS LLC | AVBP | Director10% Owner | Jan 30 '24 | Buy | $18.00 | 222,222 | $3,999,996.00 | 1,513,664 | SEC Form 4 |
| ORBIMED ADVISORS LLC | AVBP | Director10% Owner | Jan 30 '24 | Buy | $18.00 | 222,222 | $3,999,996.00 | 1,513,664 | SEC Form 4 |
Latest ARRIVENT BIOPHARMA INC News
AVBP Breaking Stock News: Dive into AVBP Ticker-Specific Updates for Smart Investing
GlobeNewswire
4 days ago
ArriVent Appoints John Hohneker, M.D., to its Board of Directors
GlobeNewswire
12 days ago
ArriVent BioPharma Reports First Quarter 2024 Financial Results
GlobeNewswire
a month ago
ArriVent Appoints Kristine Peterson to its Board of Directors
GlobeNewswire
2 months ago
ArriVent BioPharma Reports Full Year 2023 Financial Results
CNW Group
4 months ago
enCore Energy Appoints Chief Legal Officer
StockStory
4 months ago
Brinker International (EAT) Q2 Earnings: What To Expect
Zacks
4 months ago
Why Virgin Galactic (SPCE) Outpaced the Stock Market Today
PR Newswire
4 months ago